{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:42:18Z","timestamp":1790649738445,"version":"4.1.0"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T00:00:00Z","timestamp":1512000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0188943","type":"journal-article","created":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T13:34:00Z","timestamp":1512048840000},"page":"e0188943","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":72,"title":["Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4085-8784","authenticated-orcid":true,"given":"Alexandre","family":"Guilhem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Emmanuelle","family":"Fargeton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Duffau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Robert","family":"Harle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lavigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-France","family":"Carette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bletry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Kaminsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Leguy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Lerolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Chinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Dupuis-Girod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Rivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,11,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fgene.2015.00035","article-title":"Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia","volume":"6","author":"DS Ardelean","year":"2015","journal-title":"Front Genet"},{"key":"ref2","first-page":"855","article-title":"Rendu-Osler disease: clinical and molecular update","volume":"26","author":"S Bailly","year":"2010","journal-title":"M\u00e9decine Sci MS"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/e3301fb2-ae1d-471a-aaf7-f38b4c989aff","article-title":"The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors\u2014A Meta-Analysis and Systematic Review","volume":"8","author":"L Amit","year":"2013","journal-title":"PLoS ONE"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00277-006-0147-8","article-title":"Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab","volume":"85","author":"D Flieger","year":"2006","journal-title":"Ann Hematol"},{"key":"ref5","first-page":"210","article-title":"Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia","volume":"14","author":"A Mitchell","year":"2008","journal-title":"Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2012.250","article-title":"Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output","volume":"307","author":"S Dupuis-Girod","year":"2012","journal-title":"JAMA"},{"key":"ref7","unstructured":"R: The R Project for Statistical Computing [Internet]. [cited 10 Sep 2017]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.r-project.org\/\" xlink:type=\"simple\">https:\/\/www.r-project.org\/<\/ext-link>"},{"key":"ref8","first-page":"53","article-title":"Validity and reliability of lupus activity measures in the routine clinic setting","volume":"19","author":"M Petri","year":"1992","journal-title":"J Rheumatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.autrev.2011.06.011","article-title":"The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment","volume":"11","author":"KMAC Luijten","year":"2012","journal-title":"Autoimmun Rev"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e17520","DOI":"10.1371\/journal.pone.0017520","article-title":"Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985\u20132010","volume":"6","author":"B Rehal","year":"2011","journal-title":"PloS One"},{"key":"ref11","first-page":"818","article-title":"Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression","volume":"90","author":"H Sadick","year":"2005","journal-title":"Haematologica"},{"key":"ref12","unstructured":"Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E,et al. Metafore study: 8 years later. Follow-up of HHT patients treated with bevacizumab for severe hepatic vascular malformations and high cardiac output. 12th HHT international conference, Croatia; 2017."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2174\/092986706777585059","article-title":"Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic","volume":"13","author":"G Ranieri","year":"2006","journal-title":"Curr Med Chem"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/ajmg.a.36936","article-title":"The ACVRL1 c.314-35A&gt;G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations","volume":"167","author":"L Pawlikowska","year":"2015","journal-title":"Am J Med Genet A"},{"key":"ref15","first-page":"67","article-title":"Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14","volume":"6","author":"TGW Letteboer","year":"2015","journal-title":"Front Genet"},{"key":"ref16","first-page":"1741","article-title":"Hereditary hemorrhagic telangiectasia: to transplant or not to transplant?","volume":"36","author":"S Dupuis-Girod","year":"2016","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/alr.21587","article-title":"Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature","volume":"5","author":"NP Arizmendez","year":"2015","journal-title":"Int Forum Allergy Rhinol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"792","DOI":"10.4240\/wjgs.v8.i12.792","article-title":"Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia","volume":"8","author":"G Ou","year":"2016","journal-title":"World J Gastrointest Surg"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s10637-010-9549-5","article-title":"Treatment of bevacizumab-induced hypertension by amlodipine","volume":"30","author":"O Mir","year":"2012","journal-title":"Invest New Drugs"},{"key":"ref20","first-page":"360","article-title":"Rituximab-induced serum sickness in overlapping syndrome between sj\u00f6gren syndrome and systemic lupus erythematosus","volume":"19","author":"P Ungprasert","year":"2013","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrrheum.2011.205","article-title":"Hypoxia\u2014a key regulator of angiogenesis and inflammation in rheumatoid arthritis","volume":"8","author":"S Konisti","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1136\/ard.2009.119776","article-title":"Synovial tissue hypoxia and inflammation in vivo","volume":"69","author":"CT Ng","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref23","first-page":"49","article-title":"Severe hypophosphataemia after intravenous iron administration","volume":"72","author":"A Blazevic","year":"2014","journal-title":"Neth J Med"},{"key":"ref24","first-page":"191","article-title":"Optimal management of hereditary hemorrhagic telangiectasia","volume":"5","author":"N Garg","year":"2014","journal-title":"J Blood Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1086\/511645","article-title":"Hemorrhagic hereditary telangiectasia (Rendu-Osler disease) and infectious diseases: an underestimated association","volume":"44","author":"S Dupuis-Girod","year":"2007","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40261-014-0222-1","article-title":"Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups","volume":"34","author":"W-X Qi","year":"2014","journal-title":"Clin Drug Investig"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.critrevonc.2015.02.007","article-title":"Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials","volume":"94","author":"W-X Qi","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e1966","DOI":"10.1097\/MD.0000000000001966","article-title":"Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia: Be Cautious: A Case Report","volume":"94","author":"Q Maestraggi","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1002\/cncr.28343","article-title":"Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022)","volume":"119","author":"J Fangusaro","year":"2013","journal-title":"Cancer"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00280-014-2456-2","article-title":"Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients","volume":"73","author":"KM Slusarz","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/SAP.0b013e3181828141","article-title":"A review on bevacizumab and surgical wound healing: an important warning to all surgeons","volume":"62","author":"CR Gordon","year":"2009","journal-title":"Ann Plast Surg"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdq587","article-title":"Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes","volume":"22","author":"F a. B Schutz","year":"2011","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"ref33","article-title":"Increased Risk of Cerebrovascular Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis","volume":"9","author":"P-Y Zuo","year":"2014","journal-title":"PLoS ONE"},{"key":"ref34","article-title":"Angiogenesis Inhibitor Bevacizumab Increases the Risk of Ischemic Heart Disease Associated with Chemotherapy: A Meta-Analysis","volume":"8","author":"X-L Chen","year":"2013","journal-title":"PLoS ONE"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1212\/WNL.0000000000001538","article-title":"Complications and mortality in hereditary hemorrhagic telangiectasia: A population-based study","volume":"84","author":"JW Donaldson","year":"2015","journal-title":"Neurology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2796.1999.00398.x","article-title":"Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients","volume":"245","author":"AD Kjeldsen","year":"1999","journal-title":"J Intern Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2500\/ar.2014.5.0091","article-title":"Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia","volume":"5","author":"AB Thompson","year":"2014","journal-title":"Allergy Rhinol Provid RI"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5045\/br.2014.49.3.192","article-title":"Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab","volume":"49","author":"JW Wee","year":"2014","journal-title":"Blood Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1080\/19420862.2015.1022693","article-title":"Dose\u2014response relationship of bevacizumab in hereditary hemorrhagic telangiectasia","volume":"7","author":"N Azzopardi","year":"2015","journal-title":"mAbs"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0188943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T11:51:55Z","timestamp":1540036315000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0188943"}},"subtitle":[],"editor":[{"given":"Vinicio A.","family":"de Jesus Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,11,30]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0188943","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,30]]}}}